Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer

NCT02546531 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Advanced Solid Tumors
Solid Tumors
Pancreatic Cancer

Interventions

BIOLOGICAL: Defactinib
BIOLOGICAL: Pembrolizumab
DRUG: Gemcitabine

Sponsor

Washington University School of Medicine

Collaborators

[object Object]
[object Object]
[object Object]